State Street SPDR Bloomberg 1-3 Month T-Bill ETF vs Medtronic PLC — how do they compare? State Street SPDR Bloomberg 1-3 Month T-Bill ETF trades at $91.52, while Medtronic PLC trades at $79.55 (market cap $106.97B). The key difference: Medtronic PLC pays a 3.45% dividend while State Street SPDR Bloomberg 1-3 Month T-Bill ETF pays none, and State Street SPDR Bloomberg 1-3 Month T-Bill ETF is trading nearer its 52-week high, Medtronic PLC nearer its low. Which is the better fit depends on your goals.
| BIL | MDT | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $91.77 | $105.35 |
52-Week Low | $91.27 | $73.75 |
Market Cap | — | $106.97B |
Enterprise Value | — | $125.71B |
Dividend Yield | — | 3.45% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Medtronic (MDT) trades at $83.57, down 0.36% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $97.50. The company reported strong revenue growth to $33.54B in 2025, with net income of $4.66B and a net margin of 13.2%. Recent acquisitions, such as Scientia Vascular (PRNewsWire, 2026-06-12), and consistent earnings beats highlight operational strength and strategic expansion in medical technology.
MDT presents a compelling investment case with a 3.5% dividend yield and undervalued metrics relative to growth, but faces risks from rising debt levels and margin pressures. Analyst sentiment is strongly bullish with 58% buy ratings, though investors should monitor execution on fiscal 2027 guidance and macroeconomic headwinds impacting healthcare spending.
Trailing returns across standard periods
Latest headlines on both assets
BIL tracks the performance of short-term U.S. Treasury bills with maturities between 1 and 3 months. It is designed for investors seeking a highly liquid, low-risk vehicle for cash management and capital preservation.
Read more on BIL →One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →